Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

2018/02/16 by Victor L. Villemagne, Vincent Doré, Samantha C. Burnham +2 · 1 citation
Medicine · Neuroscience · Psychology · #Alzheimer's disease #Alzheimer's disease research and treatments #Amyloid (mycology) #Dementia and Cognitive Impairment Research #Disease #Functional Brain Connectivity Studies #Medicine #Neuroscience #Pathology #Psychology

paper · doi:10.1038/nrneurol.2018.9

crossref issued 2018/02/16 · crossref published 2018/02/16 · crossref published-online 2018/02/16 · openalex publication_date 2018/02/16 · crossref created 2018/02/16 · crossref published-print 2018/04/01 · crossref deposited 2024/07/01 · openalex created_date 2025/10/10 · crossref indexed 2026/08/02 · openalex updated_date 2026/08/02

Citations

• Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
• Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
• Tau imaging: early progress and future directions
• Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
• Mild Cognitive Impairment
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
• Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
• Diagnosis of Alzheimer's Disease
• A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Cited by

• Dementia with Lewy bodies [wikipedia]